Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II inavolisib monotherapy and inavolisib + palbociclib + fulvestrant in Japanese solid tumors and PIK3CA-mutated HR+/HER2- breast cancer
jRCT2031250161Phase 2Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of inavolisib in Nonhematologic neoplasms and breast cancer (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity (DLT) of inavolisib, Safety (Stage 1) and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
inavolisib
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on jRCT2031250161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250161.